Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (24012)	8/5/1998 6:43:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

bob, I agree that the uploaded article has quite a bit a relevance to LGND in particular and Biotechs in general. LGND is very complicated and the street really doesn't get it yet. Failures by smaller Biotechs have kept away investors who can't distinguish between the strong companies and the weak ones. The sector has been beaten up recently and those that are patient and in the correct stocks will be rewarded. Meanwhile, the threads will be inundated with the naysayers who post more and more of their nonsense.

To: bob zagorin who wrote (24012)	8/5/1998 7:13:00 PM
From: Henry Niman	Respond to of 32384

Speaking of interesting comments, tomorrow's NEJM will have an interesting article on use of clondronate to prevent the spread of breast cancer: paradise-web.com Not surprisingly, they talk about combination therapy, which relates to McCamant's comments on new therapies for cancer. As I have said many times before, I think that most diseases, including cancer, will be treated with a combination of drugs with increasing frequency.